Company intelligence / Profile preview

SONIRE Therapeutics

Chuo-ku, Tokyo, Japansonire-therapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

SONIRE Therapeutics has developed a next-generation ultrasound-guided high-intensity focused ultrasound (HIFU) device, "Suizenji," for non-invasive treatment of unresectable pancreatic cancer. The company’s lead program is in Phase II clinical trials in Japan and preparing for U.S. trials. The technology enables precise visualization of cavitation bubbles to improve safety and efficacy, aiming to reduce treatment sessions compared to conventional radiotherapy. Early results suggest significant survival benefit when HIFU is combined with chemotherapy. Suizenji received FDA Breakthrough Device designation in October 2024.

Therapeutic areas: Oncology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Hirata Corporation (manufacturing partner)

Beyond the preview

Go deeper on SONIRE Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SONIRE Therapeutics.